Heyu Biological Technology (OTCMKTS:HYBT – Get Free Report) and Arvinas (NASDAQ:ARVN – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.
Volatility & Risk
Heyu Biological Technology has a beta of -17.74, indicating that its stock price is 1,874% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500.
Institutional and Insider Ownership
95.2% of Arvinas shares are held by institutional investors. 89.2% of Heyu Biological Technology shares are held by insiders. Comparatively, 7.3% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Heyu Biological Technology | 0 | 0 | 0 | 0 | 0.00 |
| Arvinas | 2 | 3 | 5 | 1 | 2.45 |
Arvinas has a consensus target price of $14.17, indicating a potential upside of 53.99%. Given Arvinas’ stronger consensus rating and higher possible upside, analysts clearly believe Arvinas is more favorable than Heyu Biological Technology.
Valuation and Earnings
This table compares Heyu Biological Technology and Arvinas”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Heyu Biological Technology | $80,000.00 | 151.00 | -$270,000.00 | N/A | N/A |
| Arvinas | $262.60 million | 2.26 | -$80.80 million | $0.10 | 92.00 |
Heyu Biological Technology has higher earnings, but lower revenue than Arvinas.
Profitability
This table compares Heyu Biological Technology and Arvinas’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Heyu Biological Technology | -453.55% | -6.43% | -4.43% |
| Arvinas | 2.94% | 1.91% | 1.29% |
Summary
Arvinas beats Heyu Biological Technology on 10 of the 13 factors compared between the two stocks.
About Heyu Biological Technology
Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.
About Arvinas
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Receive News & Ratings for Heyu Biological Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heyu Biological Technology and related companies with MarketBeat.com's FREE daily email newsletter.
